Agios Financial Statements From 2010 to 2026

AGIO Stock

USD 28.54 1.07 3.90%

Agios Pharm's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Agios Pharm's valuation are provided below:

Gross Profit

-295.2 M

Market Capitalization

1.6 B

Enterprise Value Revenue

15.4448

Revenue

44.8 M

Earnings Share

(7.01)

We have found one hundred twenty available fundamental signals for Agios Pharm, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Agios Pharm's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 8th of January 2026, Market Cap is likely to grow to about 1.6 B. Also, Enterprise Value is likely to grow to about 1.5 B

Agios Pharm Total Revenue

63.09 Million

Check Agios Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharm's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8 M, Interest Expense of 15.4 M or Selling General Administrative of 189.3 M, as well as many indicators such as Price To Sales Ratio of 32.84, Dividend Yield of 0.0 or PTB Ratio of 1.32. Agios financial statements analysis is a perfect complement when working with Agios Pharm Valuation or Volatility modules.

Build AI portfolio with Agios Stock

Check out the analysis of Agios Pharm Correlation against competitors.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Agios Pharm Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

2 B

1.9 B

863.1 M

Slightly volatile

Other Current Liabilities

33.5 M

53.9 M

30.3 M

Slightly volatile

Total Current Liabilities

76.2 M

93.3 M

69.9 M

Slightly volatile

Total Stockholder Equity

1.9 B

1.8 B

700.6 M

Slightly volatile

Other Liabilities

3.6 M

3.8 M

59.5 M

Slightly volatile

Property Plant And Equipment Net

52.9 M

62.7 M

46.6 M

Slightly volatile

Accounts Payable

15.4 M

19.1 M

13.7 M

Slightly volatile

Cash

65.2 M

68.6 M

210.8 M

Pretty Stable

Non Current Assets Total

842.4 M

802.2 M

262 M

Slightly volatile

Other Assets

4.8 M

4.5 M

2.1 M

Slightly volatile

Cash And Short Term Investments

608.9 M

1 B

562.7 M

Slightly volatile

Common Stock Total Equity

49.5 K

81.7 K

48 K

Slightly volatile

Common Stock Shares Outstanding

49.8 M

66.6 M

45.5 M

Slightly volatile

Short Term Investments

987.1 M

940.1 M

462.8 M

Slightly volatile

Liabilities And Stockholders Equity

2 B

1.9 B

863.1 M

Slightly volatile

Non Current Liabilities Total

44.9 M

47.3 M

91.1 M

Very volatile

Other Current Assets

24.9 M

46.2 M

23.5 M

Slightly volatile

Other Stockholder Equity

1.3 B

1.9 B

1.1 B

Slightly volatile

Total Liabilities

184.1 M

140.6 M

164.6 M

Pretty Stable

Property Plant And Equipment Gross

134.1 M

127.7 M

54.6 M

Slightly volatile

Total Current Assets

609 M

1.1 B

568.3 M

Slightly volatile

Short Term Debt

26.5 M

15.1 M

30.9 M

Very volatile

Common Stock

53.8 K

84 K

48.6 K

Slightly volatile

Property Plant Equipment

21.1 M

26.4 M

19.2 M

Slightly volatile

Net Tangible Assets

633.1 M

1.3 B

603 M

Slightly volatile

Net Receivables

6.8 M

3.7 M

6.7 M

Pretty Stable

Capital Surpluse

1.7 B

2.7 B

1.4 B

Slightly volatile

Deferred Long Term Liabilities

19.2 M

20.2 M

37.3 M

Pretty Stable

Long Term Investments

770.8 M

734.1 M

217.2 M

Slightly volatile

Non Current Liabilities Other

752.4 K

792 K

53.4 M

Very volatile

Net Invested Capital

941.6 M

1.8 B

717.1 M

Slightly volatile

Net Working Capital

736.5 M

1 B

562.5 M

Slightly volatile

Capital Stock

75.7 K

84 K

65 K

Slightly volatile

Short and Long Term Debt Total

70.7 M

51.3 M

98.6 M

Slightly volatile

Long Term Debt Total

538.4 K

605.7 K

661.1 K

Slightly volatile

Capital Lease Obligations

70.7 M

51.3 M

98.6 M

Slightly volatile

Agios Pharm Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

8 M

6.5 M

6.9 M

Slightly volatile

Interest Expense

15.4 M

14.7 M

7.6 M

Slightly volatile

Selling General Administrative

189.3 M

180.3 M

87.8 M

Slightly volatile

Total Revenue

63.1 M

42 M

54.7 M

Pretty Stable

Other Operating Expenses

320.7 M

531.6 M

292.5 M

Slightly volatile

Research Development

233.5 M

346.5 M

210.8 M

Slightly volatile

Cost Of Revenue

3.6 M

3.7 M

59.7 M

Slightly volatile

Total Operating Expenses

316.4 M

526.8 M

288.7 M

Slightly volatile

Total Other Income Expense Net

1.4 B

1.3 B

241.6 M

Slightly volatile

Preferred Stock And Other Adjustments

3.3 M

3.7 M

4.1 M

Slightly volatile

Non Operating Income Net Other

35.5 M

33.8 M

13.4 M

Slightly volatile

Interest Income

58.1 M

55.3 M

15.3 M

Slightly volatile

Reconciled Depreciation

6.2 M

5.1 M

6.9 M

Pretty Stable

Discontinued Operations

1.6 B

1.8 B

1.9 B

Slightly volatile

Agios Pharm Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

42.1 M

49.3 M

36.9 M

Slightly volatile

Begin Period Cash Flow

111.3 M

101.4 M

100.5 M

Slightly volatile

Depreciation

6.6 M

6.5 M

5.8 M

Slightly volatile

Capital Expenditures

1.8 M

1.9 M

5.5 M

Very volatile

End Period Cash Flow

111.2 M

87.7 M

101.9 M

Pretty Stable

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

32.84

46.03

44.3564

Slightly volatile

PTB Ratio

1.32

1.39

5.5539

Slightly volatile

Days Sales Outstanding

35.86

36.98

37.8118

Slightly volatile

Book Value Per Share

25.63

24.41

12.7354

Slightly volatile

Stock Based Compensation To Revenue

0.65

1.06

0.9284

Slightly volatile

Capex To Depreciation

0.33

0.34

1.3725

Slightly volatile

PB Ratio

1.32

1.39

5.5539

Slightly volatile

EV To Sales

29.58

45.56

40.4771

Slightly volatile

Payables Turnover

0.27

0.29

5.8671

Slightly volatile

Sales General And Administrative To Revenue

1.56

1.49

1.1316

Slightly volatile

Research And Ddevelopement To Revenue

4.1

7.43

5.8411

Slightly volatile

Capex To Revenue

0.0395

0.0416

0.1182

Very volatile

Cash Per Share

11.18

14.16

13.4556

Slightly volatile

Days Payables Outstanding

1.2 K

1.3 K

Slightly volatile

Current Ratio

6.33

10.71

7.7466

Slightly volatile

Tangible Book Value Per Share

25.63

24.41

12.7354

Slightly volatile

Receivables Turnover

13.37

10.21

19.1016

Slightly volatile

Graham Number

109

97.84

107

Slightly volatile

Shareholders Equity Per Share

25.63

24.41

12.7354

Slightly volatile

Debt To Equity

0.0404

0.0425

0.1411

Slightly volatile

Capex Per Share

0.0324

0.0341

0.1239

Pretty Stable

Graham Net Net

8.14

12.49

9.7081

Slightly volatile

Revenue Per Share

0.7

0.74

1.2039

Slightly volatile

Interest Debt Per Share

1.05

0.9

1.4334

Very volatile

Debt To Assets

0.0374

0.0394

0.1014

Slightly volatile

Price Book Value Ratio

1.32

1.39

5.5539

Slightly volatile

Days Of Payables Outstanding

1.2 K

1.3 K

Slightly volatile

Company Equity Multiplier

1.78

1.24

1.6951

Slightly volatile

Long Term Debt To Capitalization

0.11

0.13

0.1402

Slightly volatile

Total Debt To Capitalization

0.039

0.041

0.1209

Slightly volatile

Debt Equity Ratio

0.0404

0.0425

0.1411

Slightly volatile

Quick Ratio

6.42

10.4

7.8349

Slightly volatile

Cash Ratio

1.03

1.08

2.9429

Pretty Stable

Days Of Sales Outstanding

35.86

36.98

37.8118

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.13

1.15

1.0463

Very volatile

Price To Book Ratio

1.32

1.39

5.5539

Slightly volatile

Fixed Asset Turnover

0.73

0.77

3.1833

Slightly volatile

Debt Ratio

0.0374

0.0394

0.1014

Slightly volatile

Price Sales Ratio

32.84

46.03

44.3564

Slightly volatile

Asset Turnover

0.024

0.0252

0.0938

Slightly volatile

Price Fair Value

1.32

1.39

5.5539

Slightly volatile

Agios Pharm Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

1.6 B

1.1 B

2 B

Very volatile

Enterprise Value

1.5 B

1.1 B

1.9 B

Very volatile

Agios Fundamental Market Drivers

	Forward Price Earnings	2.4655
	Cash And Short Term Investments	893.7 M

Agios Upcoming Events

	22nd of February 2024 Upcoming Quarterly Report	View
	2nd of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	22nd of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Agios Pharm Financial Statements

Agios Pharm investors utilize fundamental indicators, such as revenue or net income, to predict how Agios Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	-19.3 M	-18.3 M
Total Revenue	42 M	63.1 M
Cost Of Revenue	3.7 M	3.6 M
Stock Based Compensation To Revenue	1.06	0.65
Sales General And Administrative To Revenue	1.49	1.56
Research And Ddevelopement To Revenue	7.43	4.10
Capex To Revenue	0.04	0.04
Revenue Per Share	0.74	0.70
Ebit Per Revenue	(13.41)	(12.74)

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving against Agios Stock

0.84	MRK	Merck Company Sell-off Trend	Pair Corr
0.82	FTV	Fortive Corp	Pair Corr
0.78	CSCO	Cisco Systems	Pair Corr
0.71	TRV	The Travelers Companies	Pair Corr
0.64	AMGN	Amgen Inc	Pair Corr

The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.

The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:

How To Invest In Agios

Details

Is Agios Stock a good investment?

Details

What is Agios Pharm's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Agios Pharm Correlation against competitors.

To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.01)

Revenue Per Share

0.777

Quarterly Revenue Growth

0.437

Return On Assets

(0.19)

Return On Equity

(0.28)

The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Agios Financial Statements From 2010 to 2026

Agios Pharm Total Revenue

63.09 Million

Agios Pharm Balance Sheet

Agios Pharm Income Statement

Agios Pharm Cash Flow Statement

Financial Ratios

Agios Pharm Valuation Data

Agios Fundamental Market Drivers

Agios Upcoming Events

About Agios Pharm Financial Statements

Pair Trading with Agios Pharm

Moving against Agios Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY